OncoOne

The pioneers for oxMIF
We discovered it, we named it, we are drugging it!
OncoOne has overcome the limitations of targeting macrophage migration inhibitory factor by harnessing the high specificity of the structural isoform, oxidized macrophage migration inhibitory factor (oxMIF), for sites of inflammation and tumors. We are focused on developing multiple proprietary drug modalities to leverage oxMIF’s potential as a target for systemic treatment of colorectal, ovarian and lung cancers, as well as for chronic inflammatory diseases.